Objective:To investigate the clinical effect of modified capecitabine combined with irinotecan (XELIRI) regimen in the treatment of platinum-resistant platinum-refractory ovarian cancer. Methods:According to the random number table method,60 patients with platinum-resistant platinum-refractory ovarian cancer treated in our hospital from June 2020 to December 2021 were divided into two groups,30 cases in each group. The control group was treated with irinotecan,and the observation group was treated with modified XELIRI regimen. The clinical efficacy,quality of life,tumor markers,survival (OS),progression-free survival (PFS) and adverse reactions were compared between the two groups. Results:The total effective rate (RR) and disease control rate (DCR) of the observation group were higher than those of the control group,the Karnofsky functional status (KPS) score was higher than that of the control group,the levels of human epididymis protein 4 (HE4),carbohydrate antigen (CA) 125 and CA199 were lower than those of the control group,and OS and PFS were longer than those of the control group (P<0.05). Conclusion:Modified XELIRI regimen in the treatment of platinum-resistant platinum-refractory ovarian cancer can control disease progression,reduce the level of tumor markers,improve the quality of life of patients,prolong the survival time of patients,and the adverse reactions did not increase.
关键词
铂耐药铂难治卵巢癌/卡培他滨/伊立替康/肿瘤标志物/生存期
Key words
Platinum-resistant platinum refractory ovarian cancer/Capecitabine/Irinotecan/Tumor markers/Survival period
维普
万方数据